Your #1 Link to a Great Pharmacy Career!
|
IDAHO |
|
|
Success Stories. Have you found a job through RPhLink?
|
Welcome to Pharmacy Job Links! Link28752 Staff Pharmacists. This 343 bed acute care hospital in western Arkansas, FortSmith, AR is looking for a staff Pharmacists to work 2-3 months 11pm - 7am shift or 7pm - 7am shift(7 days on, 7 days off). The current pharmacy team totals 30 members and the Pharmacy computer system is SMS. However the computer system be change to Pharmacon. For full confidential details, please contact our Pharmacists at 920 - 841 - 63 05 or link here to register On-line!
Link28753 Staff Pharmacists. This three hospital health care systems including a pediatric facility and a general hospital with 325 combined beds, is looking for three permanent staff Pharmacists. The shifts would rotate days and evenings. These facilities are located in San Antonio, TX. For full confidential details, please contact our Pharmacists at 920 -841 - 6305 or link here to register On-line!
Link28754A Full Time and Part Time Pharmacists. These two acute care hospitals in McHenry, IL and Woodstock, IL are looking for a full time and part time Pharmacists. Both facilities have a flexible registry and weekend only positions. They are a state of the art health care systems with drug information, pharmocokinetic software, and the newest Pyxis technology. For full confidential details, please contact our Pharmacists at RPhLink Link28754B Night Pharmacist, Staff Pharmacist, and Clinical Pharmacist. This progressive, growing Pharmacy Department currently has three positions open: Night Pharmacist, Pharmacy Practitioner (staff Pharmacist) and Pharmacy Specialist (clinical Pharmacist) in North Central Wisconsin. The night Pharmacist would work 70 hours and get paid for 80 hours (7 nights on and 7 nights off). The Pharmacy specialist will monitor drug therapy, promote safe and cost-effective use of drugs, and council patients, physicians, nurses, and others. The Pharmacy Practitioner interprets and screens medication orders to determine appropriateness of prescription, identifies duplication and drug interactions, prepares and dispenses medications, and counsels patients. An excellent salary and benefits package are included. For full confidential details, please contact our Pharmacists at RPhLink Link28755A Pharmacist. This unique opportunity for retail pharmacy position is looking for a California licensed Pharmacist to relocate to Palm Springs, CA. They are immune to chain store competition, or insurance restrictions. For full confidential details, please contact our Pharmacists at RPhLink Link28755B Pharmacy Manager. This pharmacy in Beaver Dam, WI is looking for a Pharmacy Manager. The position is based on a 42 hour per week work schedule with a third Saturday rotation. They are also looking for someone to cover vacations. They offer competitive salary and benefits including medical, life and professional liability insurance, employee discounts, vacation and holiday pay program, profit sharing and a 401K retirement plan. The store hours are Monday - Friday 9am to 7pm, Saturday 9am to 4pm and is closed on Sunday and all holidays. For full confidential details, please contact our Pharmacists atRPhLink !
Link28756 Permanent or Relief Pharmacists. This facility, which combines a 100 bed hospital and a 60 bed long term care center, is looking for 1-2 pharmacists, either placement or relief. The facility is located in northwestern Washington near the ocean. Candidates with experience in inpatient, long term care, and home infusion work are preferred. The hours are Monday - Friday 7am to 3:30pm. The computer system that is being used is Meditech. For full confidential details, please contact our Pharmacists a RPhLink
Link28757 Occasional Relief Pharmacists. This retail pharmacy in Hancock, MI is looking for occasional relief Pharmacists. The Pharmacist would primarily check prescriptions and counsel patients, while the pharmacy technicians fill prescriptions and take care of the computer system Renlar. The pharmacy is open Monday - Friday and runs a volume of about 200 prescriptions per day. Hancock is a university town and tourist area and is ideal for anyone interested in skiing, camping, fishing, or sailing. For full confidential details, please contact our Pharmacists at RPhLink or Link28758 Relief Pharmacist. This community retail pharmacy in Spearman,Texas seeks a Pharmacist for relief. The current staff consists of the pharmacist and one pharmacy technician. The pharmacist is responsible for filling prescriptions, counseling patients, and handling the computer work. Liberty software system is used and the Pharmacy averages a volume of 100 prescriptions per day. For full confidential details, please contact our Pharmacists at PRhLink
Director of Clinical Services; Director of Contracting; Data Analyst. This national group represents over 200 cross-continuum pharmacies has three full-time positions available is the western suburbs of chicago, IL. These jobs include developing innovation clinical programs and contracting strategies at a system level and implementation of them at the local level. Applicants should be highly motivated and committed to promoting quality, cost effective pharmaceutical care services. A PharmD with residency or similar clinical experience is required for the clinical services position. For full confidential details, please our Pharmacists at RPhLink
920 - 841 - 6305 ©2000 RPhLink.com The Pharmaceutical Care Network! All Rights Reserved. |
|
RPhLink.com The Pharmaceutical Care Network! |
|
From: Ortho McNeil Re: Topamax 12-2003 Important Drug Warning The Prescribing information for Topamax (topiramate/topiramate capsules) Tablets/Sprinkle Capsules has been revised to include a warning that TOPAMAX causes hypercloremic, non-anion gap metabolic acidosis (decreased serum bicarbonate). TOPAMAX is approved and marketed for the adjunctive treatment of partial-onset seizures, generalized tonic-clonic seizures associated with the Lennox-Gastaut syndrome in adults and children two years of age and older. Data on hyperchloremic, non-anion gap metabolic acidosis are derived from placebo-controlled trials and post-marketing experience in over 2.5 million patients. In clinical trials, the rate of occurrence of a persistently decreased serum bicarbonate ranges from 23-67% for patients treated with topiramate and 1-10% for placebo. The incidence of markedly low serum bicarbonate in clinical trials ranges from 3-11% for topiramate and 1 to <1% for placebo. Generally, decreases in serum bicarbonate occur soon after initiation of topiramate, although they can occur at any time during treatment. Bicarbonate decrements are usually mild-moderate, with an average decrease of 4mEQ/L at daily doses of 400 mg in adults and approximately 6 mg/kg/day in pediatric patients. Rarely, patients can experience decrements to values below 10 mEq/L. Conditions or therapies that predispose to acidosis (such as renal disease, severe respiratory disorders, status epilepticus, diarrhea, surgery, ketogenic diet, or drugs) may be additive to the bicarbonate lowering effects of topiramate. Some manifestations of acute or chronic metabolic acidosis may include hyperventilation, nonspecific symptoms such s fatigue and anorexia, or more sever sequelae including cardiac arrhythmias or stupor. Chronic, untreated metabolic acidosis may increase the risk for nephrolithiasis or nephrocalcinosis, and may also result in osteomalacia (referred to as rickets in pediatric patients) and/or osteoporosis with an increased risk for fractures. Chronic metabolic acidosis in pediatric patients may also reduce growth rates. A reduction in growth rate may eventually decrease the maximal height achieved. The effect of topiramate on growth and bone-related sequelae has not been systematically investigated. Measurement of baseline and periodic serum bicarbonate during topiramate treatment is recommended. If metabolic acidosis develops and persists, consideration should be given to reducing the dose or discontinuing topiramate (using dose tapering). If the decision is made to continue patients on topiramate in the face of persistent acidosis, alkali treatment should be considered. The following has been added to TOPAMAX prescribing information. Under WARNINGS Metabolic Acidosis Hyperchloremic, non-anion gap, metabolic acidosis (i.e., decreased serum bicarbonate below the normal reference range in the absence of chronic respiratory alkalosis) is associated with topiramate treatment. This metabolic acidosis is caused by renal bicarbonate loss due to the inhibitory effect of topiramate on carbonic anhydrase. Such electrolyte imbalance has been observed with the use of topiramate in placebo-controlled clinical trials and in the post-marketing period. Generally, topiramate-induced metabolic acidosis occurs early in the treatment although cases can occur at any time during treatment. Bicarbonate decrements are usually mild-moderate (average decrease of 4mEq/L at daily doses of 400 mg in adults and at approximately 6 mg/kg/day in pediatric patients); rarely, patients can experience severe decrements to values below 10mEq/L. Conditions or therapies that predispose to acidosis (such as renal disease, severe respiratory disorders, status epilepticus, diarrhea, surgery, ketogenic diet, or drugs) may be additive to the bicarbonate lowering effects of topiramate. In adults, the incidence of persistent treatment-emergent decreases in serum bicarbonate (levels of <20 mEq/L at two consecutive visits or at the final visit) in controlled clinical trials for adjunctive treatment of epilepsy was 32% for 400 mg/day, and !% for placebo. Metabolic acidosis has been observed at doses as low as 50 mg/day. The incidence of a markedly abnormally low serum bicarbonate (i.e., absolute value <17mEq/L and >5 mEq/L decrease from pretreatment) in these trials was 3% for 400 mg/day, and 0% for placebo. Serum bicarbonate levels have not been systematically evaluated at daily doses greater than 400 mg/day. In pediatric patients (<16 years of age), the incidence of persistent treatment-emergent decreases in serum bicarbonate in placebo-controlled trials for adjunctive treatment of Lennox-Gastaut Syndrome or refractory partial onset seizures was 67% for TOPAMAX (at approximately 6 mg/kg/day), and 10% for placebo. The incidence of a markedly abnormally low serum bicarbonate (i.e., absolute value <17mEq/L and >5mEq/L decrease from pretreatment) in these trials was 11% for TOPAMAX and 0% for placebo. Cases of moderately severe metabolic acidosis have been reported in patients as young as 5 months old, especially at daily doses above 5 mg/kg/day. Although not approved for the prophylaxis of migraine, the incidence of persistent treatment-emergent decreases in serum bicarbonate in placebo-controlled trials for adults for prophylaxis of migraine was 44% for 200 mg/day, 39% for 100 mg/day, 23% for 50 mg/day, and 7% for placebo. The incidence of a markedly abnormally low serum bicarbonate (i.e., absolute value<17 mEq/L and >5mEq/L decrease from pretreatment) in these trials was 11% for 200 mg/day, 9% for 100 mg/day, 2% for 50 mg/day, and 1% for placebo. Some manifestations of acute or chronic metabolic acidosis may include hyperventilation, nonspecific symptoms such as fatigue and anorexia, or more severe sequelae including cardiac arrhythmias or stupor. Chronic, untreated metabolic acidosis may increase the risk for nephrolithiasis or nephrocalcinosis, and may also result in osteomalacia (referred to as Rickets in pediatric patients) and / or osteoporosis with an increased risk for fractures. Chronic metabolic acidosis in pediatric patients may also reduce growth rates. A reduction in growth rates may eventually decrease the maximal height achieved. The effect of topiramate on growth and bone related sequelae has not been systematically investigated. Measurement of baseline and periodic serum bicarbonate during topiramate treatment is recommended. If metabolic acidosis develops and persists, consideration should be given to reducing the dose or discontinuing topiramate (using dose tapering). If the decision is made to continue patients on topiramate in the face or persistent acidosis, alkali treatment should be considered. Under Precautions: Laboratory Tests Measurement of baseline and periodic serum bicarbonate during topiramate treatment is recommended ( see WARNINGS). Pediatric Use: Safety and effectiveness in patients below the age of 2 years have not been established. Topiramate is associated with metabolic acidosis. Chronic untreated metabolic acidosis in pediatric patients may cause osteomalacia (rickets) and may reduce growth rates. A reduction in growth rate may eventually decrease the maximal height achieved. The effect of topiramate on growth and bone-related sequelae has not been systematically investigated (see Warnings). Under OVERDOSE: Topiramate overdose has resulted in severe metabolic acidosis (see WARNINGS). You can further our understanding of adverse events by reporting all cases to Ortho-McNeil at the contact numbers listed below or to the FDA MedWatch Program by phone (1-800 FDA 1088), by fax (1-800-FDA-0178, by mail (using postage paid form to MedWatch, FDA, 5600 Fishers Lane, Rockville, MD 20852-9787) or via www.accessdata.fda.gov/scripts//medwatch/. A copy of the full Prescribing Information is enclosed for your reference. If you have any questions regarding TOPOMAX tablets and TOPOMAX Sprinkle Caplets, please feel free to call Ortho-McNeil Medical Affairs Division at 1-800-682-6532 Sincerely, Joseph Hulihan, MD Group Director, CNS Research Ortho-McNeil Pharmaceutical, Inc. 1000 Route 202, PO Box 300 Raritan, NJ 08869-0602 908-218-6000 Telephone |